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Practical Guidelines for the Surgical Treatment of Gallbladder 
Cancer
At present, surgical treatment is the only curative option for gallbladder (GB) cancer. Many 
efforts therefore have been made to improve resectability and the survival rate. However, 
GB cancer has a low incidence, and no randomized, controlled trials have been conducted 
to establish the optimal treatment modalities. The present guidelines include recent 
recommendations based on current understanding and highlight controversial issues that 
require further research. For T1a GB cancer, the optimal treatment modality is simple 
cholecystectomy, which can be carried out as either a laparotomy or a laparoscopic 
surgery. For T1b GB cancer, either simple or an extended cholecystectomy is appropriate. 
An extended cholecystectomy is generally recommended for patients with GB cancer at 
stage T2 or above. In extended cholecystectomy, a wedge resection of the GB bed or a 
segmentectomy IVb/V can be performed and the optimal extent of lymph node dissection 
should include the cystic duct lymph node, the common bile duct lymph node, the lymph 
nodes around the hepatoduodenal ligament (the hepatic artery and portal vein lymph 
nodes), and the posterior superior pancreaticoduodenal lymph node. Depending on patient 
status and disease severity, surgeons may decide to perform palliative surgeries.
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INTRODUCTION 
According to the Korea Central Cancer Registry’s annual report of 2011, as published 
by the Korean Ministry of Health and Welfare, gallbladder (GB) cancer accounts for 
1.1% of all cancers in Korea, making it the 11th most prevalent cancer in the country 
(1). In patients aged 65 yr or older, it is the fifth most prevalent cancer. Its incidence 
continually increased between 1999 and 2002 and given that Korea is an aging society, 
this trend is expected to continue. It is therefore imperative to establish practical guide-
lines for the diagnosis and appropriate treatment of GB cancer.
 GB cancer can be cured with radical surgery, and many efforts have been made in 
the attempt to improve resectability and the survival rate. However, GB cancer has a 
low incidence, and no randomized, controlled trials have been conducted to establish 
the optimal treatment modalities. Although a few retrospective studies have been con-
ducted in large series of patients with GB cancer, these have been limited in scope. 
Treatment guidelines for GB cancer have been published in peer-reviewed journals in 
countries outside of Korea, but these have been limited in their provision of established, 
evidence-based rationales for the most optimum surgical treatment of GB cancer (2-4). 
The Korean Association of Hepato-Biliary and Pancreas Surgery conducted a system-
atic review of the Korean and English literature to establish standard treatment guide-
lines for GB cancer and to improve treatment outcomes. The treatment guidelines de-
scribed herein present evidence-based rationales to assist our colleagues in establish-
ing optimal treatment strategies for GB cancer patients in clinical settings. Recommen-
dations for treatment are noted (the grades of these recommendations are deﬁned in 
Table 1) and the levels of evidence are also given (in parentheses) in the reference cita-
tions (see the deﬁnitions of levels in Table 2).
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Table 1. Definitions of evidence by level 
Levels Definition of evidence 
1 Evidence obtained from systematic review (SR) of all the randomized  
   controlled trials (RCTs)
2 Evidence obtained from more than one well-controlled RCT
3 Evidence obtained from well-controlled trials (CT), multi-center cohorts,  
   or case-control studies or that were obtained from longitudinal studies  
   without intervention
4 Evidence obtained from the clinical experiences of key opinion leaders or  
   those obtained from study
Table 2. Recommendation levels 
Level of recommendation Conditions
A There is a sufficient amount of clinical evidence to make convincing recommendations and agreement has been reached among the board  
   members as to the appropriateness of recommendations.
B There is an insufficient amount of clinical evidence. However, based on low-level clinical evidence, agreement has still been reached among the  
   board members as to the appropriateness of these recommendations.
C Recommendations have been made based on low-level clinical evidence. No agreement has been reached on whether such recommendations  
   are appropriate, although there is no great disagreement among the board members.
D There is great disagreement among the board members on the recommendations.
Table 3. Summary of recommendations for patients with suspicious GB cancer
Surgical intervention Level of evidence Level of recommendation
Patients may undergo laparoscopic cholecystectomy unless there is preoperative evidence of GB fossa invasion. 4 B
Laparotomy is recommended for definite preoperative evidence of GB fossa invasion. 3 B
Table 4. Summary of recommendations for patients with T1a GB cancer
Surgical intervention Level of evidence Level of recommendation
The optimal treatment modality for T1a GB cancer is simple cholecystectomy, which can be carried out as either a  
   laparotomy or a laparoscopic surgery.
3 A
A histopathologic examination should be performed to evaluate whether there is invasion in the resection margin of the  
   cystic duct.
3 A
Intraoperative perforation of the GB should be avoided, and the resected GB should be removed using a vinyl bag during  
   laparoscopic surgery.
3 A
SURGICAL APPROACHES FOR PATIENTS WITH 
SUSPECTED GB CANCER
According to published treatment guidelines, it is recommend-
ed that patients undergo laparotomy if they are suspected of hav-
ing GB cancer based on the preoperative work-up (2, 3). This is 
based on the rationale that GB cancer should be treated by sur-
gical modalities, such as laparotomic cholecystectomy, hepa-
tectomy for GB fossa, and lymph node dissection. However, 
several recent studies have recommended that a simple chole-
cystectomy should be the standard treatment modality for T1 
GB cancer (5-11). Laparoscopic cholecystectomy has shown 
equivalent or better treatment outcomes compared to those for 
laparotomy (5-7). This has led to the sugggestion that patients 
should undergo laparoscopic cholecystectomy unless there is 
evidence of invasion to the GB fossa (Level of evidence 4, Level 
of recommendation B). Otherwise, a laparotomy would be ad-
vised (Level of evidence 3, Level of recommendation B). Table 3 
summarizes the recommendation for suspected GB cancer.
SURGICAL TREATMENT FOR EARLY GB CANCER
T1a GB cancer
Based on a literature review, simple cholecystectomy is the op-
timal treatment for patients with T1a GB cancer confined to 
mucosa. Laparoscopic cholecystectomy is also an appropriate 
modality (5-8, 12, 13). The five-year survival rate for simple cho-
lecystectomy is as high as 95%-100%. An extended cholecystec-
tomy is not effective in prolonging long-term survival unless 
there are tumor invasions into the resection margin of the cystic 
duct (9). According to a systematic review of the T1a GB cancer 
literature, the recurrence rate is 1.1% in such cases. The most 
frequent site of recurrence was the common bile duct (6) (more 
than 50% of the total cases). Therefore, histopathologic exami-
nation should be performed to determine whether there are tu-
mor invasions into the resection margin of the cystic duct. If 
this is the case, extrahepatic bile duct (EHBD) resection should 
be considered (6, 7) (Level of evidence 3, level of recommenda-
tion A). Lymph node metastasis has been reported in less than 
2.5% of total cases; therefore, lymph node dissection is not rec-
ommended for patients with T1a GB cancer (6, 10). The five-
year survival rate is estimated at 100% for T1a GB patients who 
undergo laparoscopic cholecystectomy (6, 7), but there are some 
reports that bile juice leakage during laparoscopic cholecystec-
tomy is associated with peritoneal metastasis and tumor recur-
rence at trocar sites. As such the surgical procedure should be 
carefully performed so as to prevent intraoperative GB perfora-
tion, and the resected GB should be removed using a vinyl bag 
(6, 12) (Level of evidence 3, level of recommendation A). Table 
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4 summarizes the recommendations for T1a GB cancer. 
T1b GB cancer
There is no clear evidence that extended cholecystectomy in-
creases survival compared to the results for simple cholecystec-
tomy in patients with T1b GB cancer (5, 6, 12). Moreover, sever-
al studies have shown that there is no significant difference in 
five-year survival between patients who undergo laparoscopic 
cholecystectomy and those who undergo laparotomy. It can 
therefore be inferred that laparoscopic cholecystectomy is not 
associated with poor prognosis (8, 11, 12). According to a sys-
tematic review of the T1 GB cancer literature, lymph node me-
tastasis is present in approximately 11% of all cases, and the re-
currence rate is 9.3% (6). However, this rate is higher in patients 
with T1b GB cancer who have undergone simple cholecystec-
tomy (5, 6). Although there is a lack of clear evidence demon-
strating that extended cholecystectomy increases patient’s sur-
vival as compared with a simple cholecystectomy, the former 
may nevertheless be recommended for patients who are not at 
increased risk of developing postoperative complications in that 
simple cholecystectomy has a relatively higher recurrence rate 
(6, 7, 9, 14) (Level of evidence 3, level of recommendation B). 
Table 5 summarizes the recommendations for T1b GB cancer.
SURGICAL TREATMENTS FOR OTHER GB CANCER 
STAGES
An extended cholecystectomy is generally recommended for 
patients with GB cancer at stage T2 or above (15-20) (Level of 
evidence 3, Level of recommendation B). In patients who are 
indicated for radical cholecystectomy, a combined approach 
can also be considered.
Extent of hepatic resection in extended cholecystectomy 
A wedge resection of the GB bed or segmentectomy IVb/V can 
be performed (Level of evidence 3, Level of recommendation 
B). In a wedge resection, it is recommended that the hepatic re-
section margin width should be proposed to be approximately 
2-3 cm; however, there is by no means universal consensus on 
this point. Table 6 summarizes the recommendations for the 
ideal extent of hepatic resection in extended cholecystectomy.
Extent of lymph node dissection in extended 
cholecystectomy 
Lymph node metastasis is a well-known prognostic indicator, 
and its incidence varies depending on the depth of mural inva-
sion as follows: pT1a, 0%-2.5%; pT1b, 5%-16%; pT2, 9%-30%; 
T3, 39%-72%; and T4, 67%-80% (6, 9, 21, 22). There is no con-
sensus on the optimum extent of lymph node dissection in ex-
tended cholecystectomy for GB cancer patients. The seventh 
edition of the AJCC Cancer Staging Manual (23), defines, re-
gional lymph node group 1 (N1) as comprising the cystic duct 
lymph node, common bile duct lymph node, and the lymph 
nodes around the hepatoduodenal ligament (i.e., the hepatic 
artery lymph node and portal vein lymph node). The posterior 
pancreaticoduodenal lymph node, celiac artery lymph node, 
superior mesenteric artery lymph node, para-aortic lymph node, 
and pericaval lymph node are classified as belonging to region-
al lymph node group 2 (N2). N2 metastasis would be interpret-
ed as remote metastasis, and such patients would be classified 
as TNM IVB. In most cases, the long-term survival cannot be 
predicted for patients with N2 metastasis, and radical lymph 
node dissection is not routinely performed (17, 24-26). Region-
al lymph node dissection is recommended for the cystic duct 
lymph node, common bile duct lymph node, the lymph nodes 
Table 5. Summary of recommendations for patients with T1b GB cancer
Surgical intervention Level of evidence Level of recommendation
There is an insufficient amount of clinical evidence demonstrating that extended cholecystectomy increases T1b GB cancer  
   patient survival. It can therefore be inferred that either simple or an extended cholecystectomy is appropriate.
3 B
There is no evidence demonstrating that a laparoscopic cholecystectomy is likely to lead to a poor prognosis. It can therefore  
   be inferred that laparoscopic cholecystectomy may be performed.
3 B
Extended cholecystectomy can be carried out in patients who are not at increased risk for developing postoperative complications. 3 B
Histopathologic examination should be performed to evaluate whether there is invasion in the resection margin of the cystic duct. 3 A
To avoid intraoperative perforation of the GB, special attention should be paid to surgical procedures. During the laparoscopic  
   surgery, the resected GB should be removed using a vinyl bag.
3 A
Table 6. Summary of recommendations for extent of hepatic resection or lymph node dissection in extended cholecystectomy
Surgical intervention Level of evidence Level of recommendation
A wedge resection of the GB bed or a segmentectomy IVb/V can be performed. 3 B
Regional lymph node dissection is routinely performed within an extended cholecystectomy. The optimal extent of lymph  
   node dissection should include the cystic duct lymph node, the common bile duct lymph node, the lymph nodes around  
   the hepatoduodenal ligament (the hepatic artery and portal vein lymph nodes), and the posterior superior  
   pancreaticoduodenal lymph node.
3 C
For accurate the determination of the TNM stage, more than three lymph nodes should be collected for histopathologic 
   examinations.
4 C
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around the hepatoduodenal ligament (hepatic artery and por-
tal vein lymph nodes), and the posterior superior pancreatico-
duodenal lymph node (Level of evidence 3, Level of recommen-
dation C). There is no consensus on the minimum or optimal 
number of resected lym ph nodes required to accurately deter-
mine the TNM stage. The sixth edition of the AJCC Staging Man-
ual stated that more than three lymph nodes are required to ac-
curately determine the N-stage. However, this point was deleted 
in the manual’s seventh edition. Some surgeons are of the opin-
ion that only 3-4 lymph nodes can be collected despite N1 re-
gional lymph node dissection although 1-2 lymph nodes can 
be collected using a simple cholecystectomy. Based on this, we 
propose that more than three lymph nodes should be collected 
for histopathologic examinations (Level of evidence 4, Level of 
recommendation C). Table 7 summarizes the recommendations 
for extent of the optimal lymph node dissection in extended cho-
lecystectomy.
Clinical significance of extrahepatic bile duct resection in 
radical surgery
Since the early 1990s, it has been maintained that EHBD resec-
tion should be performed for GB cancer irrespective of the TNM 
stage (27). This is based on the rationale that this procedure 
achieves complete lymph nodes resection around the hepato-
duodenal ligament in early GB cancer and also helps achieve 
radical tumor mass resection with perineural invasion in ad-
vanced GB cancer. However, it has been subsequently found 
that EHBD resection is not associated with increased survival 
(28-32). There are also contradictory reports that the incidence 
of early and late-stage complications is increased by this proce-
dure (28, 33). Therefore, EHBD resection should not be seen as 
mandatory in the radical resection of GB cancer but rather as 
an option to be selectively performed in specific types of cases, 
such as GB cancer with extrahepatic bile duct invasion (Level of 
evidence 3, Level of recommendation C). Table 7 summarizes 
the recommendations for EHBD resection in radical surgery.
Clinical significance of surgery in GB cancer patients with 
para-aortic lymph node metastasis
It is generally known that patients with advanced GB cancer with 
para-aortic lymph node metastasis are contraindicated in sur-
gery. However, it has been reported that survival is significantly 
prolonged following radical resection that includes para-aortic 
lymph node dissection in patients with GB cancer with para-
aortic lymph node metastasis, compared to results for patients 
with distant metastasis or advanced, unresectable GB cancer 
(34). Conversely, another study reported that patients with TNM 
stage III or IV GB cancer should undergo extended lymph node 
dissection involving the para-aortic lymph node (35). Current-
ly, surgical treatment efficacy cannot be predicted in GB cancer 
patients with para-aortic lymph node metastasis. The decision 
to perform radical surgery should thus be based on the surgeon’s 
judgment (Level of evidence 3, Level of recommendation C). 
Table 7 summarizes the recommendations for surgery in GB 
cancer patients with para-aortic lymph node metastasis.
Clinical significance of surgical treatments in patients 
with invasion of the hepatic artery, portal vein, and 
adjacent organs
Very poor prognoses are expected in advanced GB cancer cas-
es, and most patients refuse to undergo surgery when invasion 
of the hepatic artery and portal vein are suspected. Kobayashi 
et al. (36) performed analysis in 71 patients with GB cancer and 
found that the prognosis was poorer if surgeons performed a 
combined resection of the hepatic artery and portal vein for pa-
tients with invasion of both vessels as compared with results for 
those patients who had no invasion. Moreover, the authors re-
ported that invasion of the hepatic artery and portal vein is a 
key prognostic indicator (36, 37). There are no effective treat-
ment modalities other than surgery for patients with GB cancer. 
Surgical treatments are recommended for GB cancer patients if 
complete tumor removal (R0 resection) can be achieved through 
a combined resection of the hepatic artery and portal vein (Lev-
el of evidence 3, Level of recommendation C).
 Combined resection is routinely recommended for advanced 
GB cancer cases in which there is invasion of adjacent organs 
(colon and duodenum). As this requires both a combined re-
section and R0 resection, favorable prognoses are not guaran-
teed. The selection of appropriate patients is essential (38) (Level 
of evidence 3, Level of recommendation C). Table 7 summarizes 
the recommendations for surgical treatment in patients with in-
vasion of the hepatic artery, portal vein, and adjacent organs.
Table 7. Summary of recommendations for extrahepatic bile duct (EHBD) resection in radical surgery, surgery in GB cancer patients with para-aortic lymph node metastasis, 
surgical treatments in patients with invasion of the hepatic artery, portal vein, and adjacent organs, and palliative surgery in patients who are not indicated for radical surgery
Surgical resection Level of evidence Level of recommendation
EHBD resection is not mandatory for radical resection of GB cancer, but can be performed in certain cases. 3 C
In patients with GB cancer with para-aortic lymph node metastasis, radical surgery can also be performed based on the  
   surgeon’s judgment.
3 C
Both combined resection and R0 one are essential for achieving a good prognosis. A combined resection of the adjacent  
   organs cannot guarantee a good prognosis for all the patients. Selection of appropriate patients is therefore essential.
3 C
Depending on patient status and disease severity, surgeons may decide to perform palliative surgeries, such as non-radical  
   cholecystectomy, biliary bypass surgery, or gastric bypass surgery.
3 C
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Clinical significance of palliative surgery in patients who 
are not indicated for radical surgery 
The median and one-year survival rates in patients with unre-
sectable GB cancer are reported to be approximately 2-4 months 
and less than 5%, respectively. It is also known that cytoreduc-
tive surgery is not useful in patients with GB cancer (39-42). How-
ever, palliative surgery will most likely be able to prolong the 
short-term survival period and improve the quality of life of pa-
tients with unresectable GB cancer. Palliative surgery options 
here include non-radical, simple cholecystectomy. If biliary 
atresia or gastric outlet obstruction are concurrently present, 
bypass surgery would also improve patient quality of life. Sur-
geons should therefore decide the optimal treatment modality 
in view of the patient status involved (43, 44) (Level of evidence 
3, Level of recommendation C). Table 7 summarizes the rec-
ommendations for palliative surgery in patients who are not in-
dicated for radical surgery. 
TREATMENT OF INCIDENTALLY FOUND GB 
CANCER AFTER CHOLECYSTECTOMY 
GB cancer incidentally found on postoperative 
histopathology
The core principles for the surgical treatment of GB cancer inci-
dentally found on postoperative histopathology are identical to 
those described earlier. That is, no additional surgeries should 
be considered for histologically-proven T1a GB cancer if the GB 
was completely resected during surgery (5-8, 12, 13) (Level of 
evidence 3, Level of recommendation A). However, in cases of 
histologically-proven T1b GB cancer, there is still controversy 
regarding whether extended cholecystectomy or follow-up with-
out additional surgeries should be performed (5, 6, 8, 11, 12) 
(Level of evidence 3, Level of recommendation B). In cases of 
GB cancer at T2 or above, the additional use of extended chole-
cystectomy is recommended (Level of evidence 3, Level of rec-
ommendation B). There are no established reports regarding 
the timing of additional surgeries; however, some studies have 
been performed immediately after GB cancer diagnosis (45, 46) 
(Level of evidence 3, Level of recommendation C). Table 8 sum-
marizes the recommendations for GB cancer incidentally found 
on postoperative histopathology.
GB cancer incidentally found during surgery
The surgical treatment principles for histologically-proven GB 
cancer found during surgery are identical to those for GB can-
cer incidentally found on postoperative histopathology. How-
ever, in patients who are suspected of having T1 GB cancer dur-
ing surgery, it is difficult to differentiate between T1a and T1b 
GB cancers. Therefore, cholecystectomy should be the first-choice 
treatment. It is recommended that additional surgeries should 
be determined based on the postoperative histopathology (Lev-
el of evidence 4, Level of recommendation C). In GB cancer at 
T2 or above, extended cholecystectomy should be performed 
based on a tentative or revised diagnosis (Level of evidence 4, 
Level of recommendation C). Table 9 summarizes the recom-
mendations for GB cancer incidentally found during surgery.
SURGICAL TREATMENT OF GB CANCER 
ACCOMPANIED BY ACUTE CHOLECYSTITIS
GB cancer is often accompanied by bile stones, leading to acute 
cholecystitis symptoms in many cases. There are no accurate 
reports on the incidence of acute cholecystitis, although it has 
been reported to range from 8.8% to 20% (47-49). A preopera-
tive differential diagnosis of acute cholecystitis accompanied 
by GB cancer is essential for determining surgical plans, but 
there are some situations in which such a differential diagnosis 
is difficult. Indeed, surgery should possibly be delayed in pa-
tients with GB cancer who have concurrent acute cholecystitis. 
In addition, the appropriate extent of surgery cannot be intra-
operatively determined, leading to poor prognoses (50). Sur-
geons are recommended to consider the possibility of GB can-
Table 8. Summary of recommendations for GB cancer found incidentally on postoperative histopathology
Postoperative situations Level of evidence Level of recommendation
The optimal treatment modality for T1a GB cancer is a simple cholecystectomy. 3 A
There is no clear evidence demonstrating that extended cholecystectomy prolongs survival in patients with T1b GB  
   cancer. The additional use of extended cholecystectomy is thus subject to the surgeon’s judgment.
3 B
Patients with GB cancer at T2 or higher should additionally undergo extended cholecystectomy. 3 B
If surgeons determine that additional surgeries are needed, they should be performed without delay. 3 C
Table 9. Summary of recommendations for GB cancer found incidentally during surgery
Clinical conditions Level of evidence Level of recommendation
In patients suspected of having T1 GB cancer during surgery, it is difficult to differentiate between T1a and T1b cancers.  
   Therefore, cholecystectomy should be performed as the first-choice treatment, and any additional surgeries should be  
   carried out based on postoperative histopathologic findings.
4 C
In T2 or higher GB cancers, extended cholecystectomy should be performed based on a tentative or revised diagnosis. 4 C
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cer in patients who are suspected of having acute cholecystitis 
if they are older and exhibit focal GB wall thickening, a mass 
within the internal GB lumen, overall GB wall thickening with 
decreased GB size, or lymphadenopathy around the GB (51) 
(Level of evidence 4, Level of recommendation C).
POSTOPERATIVE ADJUVANT THERAPY
Complete surgical excision of GB cancer is the only radical treat-
ment modality at present, but the rate of resection is at most 
25%-30%. Nearly half of patients are at increased risk for recur-
rent GB cancer despite having undergone complete resection 
(52, 53). Recurrent GB cancer may be the result of distant me-
tastasis, but it may also be characterized by local recurrence (54-
56). Patients with recurrent GB cancer are therefore required to 
undergo local treatment modalities, such as postoperative ad-
juvant chemotherapy or concurrent chemoradiation therapy 
(CCRT). For postoperative adjuvant chemotherapy, fluoropy-
rimidine drugs such as 5-fluorouracil or capecitabine are the 
preferred choice. CCRT is also recommended to be carried out 
in conjunction with these drugs. Depending on patient status 
or surgeon preference, monotherapy or combination treatment 
regimens using gemcitabine or fluoropyrimidine may also be 
considered (6). However, postoperative adjuvant chemothera-
py or CCRT are not recommended in patients with T1 GB can-
cer who have undergone radical resection (58-60) (Level of evi-
dence 3, Level of recommendation C). Table 10 summarizes 
the recommendations for the optimum postoperative adjuvant 
therapy for GB cancer.
CONCLUSIONS
There are no randomized, prospective studies assessing the sur-
gical treatments for GB cancer. Moreover, there are only a few 
systematic reviews of the GB cancer surgical literature. There 
are many retrospective studies in this series, but when taken as 
a whole, these have the following limitations: 1) small numbers 
of enrolled patients; 2) heterogeneity of patient populations 
across studies, and 3) inconsistent surgical procedures across 
studies. Therefore, we experienced considerable difficulty in 
drawing conclusions and developing recommendations based 
on the existing clinical evidence. Nevertheless, the current re-
port is based on a systematic review of the literature and in-depth 
discussion among board members. We believe that these treat-
ment guidelines are of value for selecting the optimal surgical 
modalities in GB cancer patients.
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